News
Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G ...
Stocktwits on MSN3d
Eli Lilly Inks Up To $1.3B Deal With Superluminal Medicines To Develop Obesity Drugs
Eli Lilly (LLY) has entered into a deal worth up to $1.3 billion with drug discovery company Superluminal Medicines to advance small molecule therapeutics relevant to cardiometabolic diseases and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback